Tau PET/CT Imaging in Alzheimer's Disease
This study, called MPC-TAU, is looking at older adults who have Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD). Researchers are using a special imaging scan called a PET/CT with a substance called AV-1451. This scan helps them see "tau pathology," which are abnormal proteins in the brain linked to Alzheimer's. The goal is to understand how these tau proteins relate to other information about your health and thinking abilities. This could help us learn more about the different ways Alzheimer's Disease can affect people. You can join if you are already part of the MPC study at UPenn or MGH, are between 18 and 120 years old, and have a study partner. The study's status is currently unclear.
- Study design
- This is an observational study involving 100 participants. It is a cross-sectional study, meaning data is collected at a single point in time.
- What's involved
- You will provide informed consent and then undergo a PET/CT scan with AV-1451. A brain MRI must have been performed within 6 months before your scan.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, looking at tau patterns, is measured at 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- David A. Wolk · PRINCIPAL_INVESTIGATOR · University of Pennsylvania Department of Neurology at the Perelman School of Medicine
- Sandhitsu R. Das · PRINCIPAL_INVESTIGATOR · University of Pennsylvania Department of Neurology at the Perelman School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Clusters based on spatial pattern and extent of T-N Mismatch5 years
We will test the hypotheses that spatial pattern and directionality of deviation in individual subjects of this metric will be correlated with modulatory factors such as non-AD pathology, brain resilience and vulnerability. Specifically, we will use hierarchical clustering to determine groups based on degree and spatial pattern of mismatch between tau PET and cortical thickness measured by MRI. In these groups, we will compare amount of white matter hyperintensities, degree of brain aging, and both cross-sectional and longitudinal cognitive measures, with the primary measure being the Clinical Dementia Rating scale sum of boxes.